Stevens-Johnson syndrome
Information
- Disease name
- Stevens-Johnson syndrome
- Disease ID
- DOID:0050426
- Description
- "A skin disease that is characterized by ulceration of less than 10 percent of the surface area of the body. The disease is often precipitated by the use of medications, such as antibiotics or antiepileptics, or onset of infection." [url:https\://en.wikipedia.org/wiki/Stevens%E2%80%93Johnson_syndrome]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05520086 | Active, not recruiting | Phase 1/Phase 2 | Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis. | November 11, 2022 | February 2024 |
| NCT02149732 | Available | Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation | May 2014 | December 2016 | |
| NCT01696500 | Completed | Phase 3 | Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. | October 2012 | June 2014 |
| NCT00844038 | Completed | Stevens-Johnson Syndrome Antimicrobial | August 2008 | December 2008 | |
| NCT01488396 | Completed | Phase 4 | Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye | February 2007 | July 2009 |
| NCT02945176 | Completed | N/A | Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation | March 2015 | June 14, 2017 |
| NCT06263140 | Completed | Vitamin D Levels in Non-immediate Drug Hypersensitivity Case-control Study | May 30, 2021 | February 1, 2022 | |
| NCT03585946 | Not yet recruiting | Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis | January 1, 2024 | December 31, 2028 | |
| NCT03659227 | Recruiting | Drug Reactions Sampling (COLLECTIONTOXIDERMIES) | September 26, 2018 | September 25, 2028 | |
| NCT02987257 | Recruiting | Phase 3 | NATIENS: Optimal Management and Mechanisms of SJS/TEN | March 21, 2023 | August 1, 2028 |
| NCT02037347 | Terminated | Phase 1/Phase 2 | Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis | October 2010 | December 2014 |
| NCT03046914 | Unknown status | N/A | HLA-B*5801 Screening to Prevent Allopurinol-induced Severe Cutaneous Adverse Reaction | February 24, 2016 | November 30, 2017 |
| NCT01122303 | Unknown status | Corneal Epitheliotropic Factors in Autologous Serum Eye Drops in Nonautoimmune and Stevens-Johnson Syndrome With Dry Eye | December 2009 | December 2010 | |
| NCT04313725 | Unknown status | N/A | Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease | February 24, 2020 | March 31, 2022 |
| NCT05145959 | Unknown status | N/A | Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis | December 1, 2021 | March 1, 2024 |
| NCT05284929 | Unknown status | Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population | May 17, 2017 | March 17, 2023 | |
| NCT02126020 | Withdrawn | Phase 1/Phase 2 | Topical Infliximab in Autoimmune Eyes With Keratoprosthesis | November 2014 | April 3, 2017 |
| NCT01256489 | Withdrawn | Phase 1/Phase 2 | Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS) | December 2010 | January 2015 |
- Disase is a (Disease Ontology)
- DOID:37
- Cross Reference ID (Disease Ontology)
- EFO:0004276
- Cross Reference ID (Disease Ontology)
- GARD:7700
- Cross Reference ID (Disease Ontology)
- ICD10CM:L51.1
- Cross Reference ID (Disease Ontology)
- ICD9CM:695.13
- Cross Reference ID (Disease Ontology)
- MESH:D013262
- Cross Reference ID (Disease Ontology)
- NCI:C79484
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:73442001
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0038325
- OrphaNumber from OrphaNet (Orphanet)
- 36426
- MeSH unique ID (MeSH (Medical Subject Headings))
- D013262